BRAF and malignant colon neoplasm: However, to our surprise, treatment with AUY922 only moderately reduced the expression of mutant BRAF while it abolished the expression of other HSP90 client proteins such as CRAF and SKP2 in mutant BRAF colon cancer cells [29].